Neuroepithelial neoplasm

Researchers are testing CHANK-101, a therapy made from a patient's own natural killer (NK) cells, in adults with glioblastoma that has returned after standard treatment. The study enrolls 60 participants who receive intravenous infusions of these cells every two weeks for up to 1…

Researchers are testing an experimental therapy called SRN-101 in adults with recurrent high-grade glioma, an aggressive brain cancer that has returned after standard treatment. Participants receive SRN-101 directly into the tumor before planned surgery to remove it. The trial's …

This phase 1 trial tests a new approach for diffuse midline glioma (DMG), an aggressive brain tumor with a poor prognosis. The treatment combines focused ultrasound to temporarily open the blood-brain barrier with an infusion of immune cells engineered to attack the tumor. The st…

This trial is testing whether a new formulation of the chemotherapy drug cisplatin, called LSAM-Cisplatin, can be safely infused directly into the brain tumors of children and young adults with diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG). The t…

This trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…

This study tests a custom-made vaccine for people with two serious brain cancers: glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). The vaccine is made from the patient's own immune cells and designed to teach the body to attack the tumor. The main goals are to chec…

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…

Researchers are testing whether adding entacapone to bevacizumab is safe and can slow tumor growth in adults with glioblastoma that has returned after standard treatment. The trial enrolls about 96 participants who have not previously received bevacizumab and for whom repeat surg…

Researchers are testing an oral drug called safusidenib in adults newly diagnosed with IDH1-mutant grade 3 oligodendroglioma or astrocytoma, two types of brain tumor. Safusidenib is designed to cross into the brain and block the mutated IDH1 enzyme that drives these tumors. All 2…

Researchers are running a phase 1 trial of SHR-4595, an experimental injectable drug, in adults with advanced solid tumors that have not responded to standard treatments. The study checks how safe and tolerable the drug is, how the body processes it, and what dose might work best…

Researchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…

Researchers are testing daraxonrasib, an experimental pill that blocks RAS proteins, in children with solid tumors that have come back or stopped responding to treatment. The tumors include neuroblastoma and rhabdomyosarcoma, and all carry RAS mutations. The trial has two parts: …

Researchers are testing whether GammaTile, a collagen tile embedded with radioactive cesium-131 seeds, can be safely placed in the brain after surgery for malignant glioma. The trial enrolls elderly or frail patients with newly diagnosed or recurrent tumors. The main goals are to…

This early-phase trial tests an experimental drug called NST-628 in adults with recurrent grade 4 glioma, an aggressive brain cancer. The study aims to see how well the drug enters the tumor and affects cancer-related proteins, as well as its safety. Participants take the drug be…

This study tests a drug called ADI-PEG 20, which breaks down an amino acid that some brain tumors need to grow. It is given alongside standard radiation and chemotherapy to children, adolescents, and young adults with newly diagnosed high-grade glioma. The goal is to see if this …

Researchers are testing an experimental antibody called 3SC009 in adults with advanced or metastatic solid tumors that have not responded to other treatments. The drug is a bispecific antibody, meaning it binds to two different targets on cancer cells, CD47 and EpCAM. The trial h…

This study tests a new treatment called Cerebraca Wafer for people with recurrent glioblastoma, a serious brain cancer. The wafer is placed in the brain during surgery and is followed by standard chemotherapy. The goal is to see if it helps people live longer and controls the dis…

Researchers are testing an investigational oral drug called catequentinib hydrochloride (AL3818) in adults with advanced or metastatic endometrial cancer, low grade serous ovarian cancer, soft tissue sarcoma, or glioblastoma. The trial has two parts: a phase 1b part to find safe …

This early-phase study tests a new treatment for children and young adults with aggressive brain tumors called high-grade glioma and DIPG. The therapy uses the patient's own immune cells, modified in a lab to better recognize and attack tumor cells. The main goals are to see if t…

This study tests adding a new drug, iberdomide, to standard chemoimmunotherapy for children and young adults (ages 1-30) whose neuroblastoma has returned, not responded, or worsened after prior treatment. The goal is to see if the combination is safe and works better at controlli…

This study is for adolescents and young adults (ages 12-39) newly diagnosed with aggressive brain tumors called high-grade glioma or DIPG. The goal is to see if a combination of two immunotherapy drugs (relatlimab and nivolumab, sold as Opdualag) is safe and tolerable when given …

This early-stage trial tests an investigational drug called HP007, given as an injection directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments or have come back. The main goals are to check the drug's safety, find the right dose…

This clinical trial tests a new type of immunotherapy called 4SCAR-T, which uses a patient's own immune cells engineered to recognize and attack three different markers (GD2, PSMA, and CD276) on neuroblastoma cancer cells. The study enrolls children and adults (ages 1 to 65) with…

This first-in-human trial tests an experimental drug called BD200 in adults with advanced solid tumors that have not responded to standard treatments. BD200 is designed to latch onto two proteins, Trop-2 and Nectin-4, found on many cancer cells, potentially delivering a toxic pay…

This study tests a new treatment called 4sCAR-DLL3 CAR-T cells for people with DLL3-positive brain tumors, including glioblastoma and certain midline gliomas. The therapy uses a patient's own immune cells, modified to target and attack tumor cells. The trial will enroll 30 partic…

This Phase 2 trial tests an investigational drug called MK-2010, which is designed to help the immune system attack cancer. Researchers will give MK-2010 alone or in combination with other treatments to about 480 people with advanced solid tumors, meaning cancers that have spread…

This study tests an experimental drug called safusidenib in people with a slow-growing brain tumor (IDH1-mutant glioma) whose tumor got worse while on the standard drug vorasidenib. Up to 40 participants take safusidenib pills twice daily to see if the tumor shrinks or stops grow…

This phase 1 trial tests whether FPS-ZM1, a drug that blocks an inflammation pathway, can safely control brain swelling that often occurs after surgery for glioblastoma, a type of brain cancer. Researchers will give FPS-ZM1 with or without the steroid dexamethasone to about 24 ad…

This study tests a new therapy using a patient's own immune cells, engineered to target a specific mutation found in diffuse midline glioma and DIPG, aggressive brain tumors. About 30 participants with recurrent or refractory disease will receive one to two infusions of these cel…

This phase 1/2 trial tests an investigational drug called HY07121, given as a subcutaneous injection, in adults with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study has two parts: the first finds a safe dos…

This trial tests whether adding hyperbaric oxygen therapy to a standard immunotherapy-chemotherapy combination can help people with newly diagnosed glioblastoma. Participants receive either adebrelimab plus temozolomide alone, or the same drugs with hyperbaric oxygen sessions. Th…

This early-phase trial is testing an investigational drug called FL115 in adults with advanced solid tumours that have progressed after standard therapy or for whom no standard treatment exists. FL115 is designed to stimulate the immune system's natural killer cells and T cells t…

This early-stage trial tests a new cancer treatment called OTS-412, a modified virus designed to attack tumor cells. It is given alone or with hydroxyurea and the immunotherapy atezolizumab. The study includes 24 adults with advanced solid tumors that no longer respond to standar…

This early-stage trial is testing an experimental drug called LAE118 in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The study will evaluate the drug's safety and tolerability when given alone or combined with other anti-cancer medicati…

This trial is testing whether giving tarlatamab before and after surgery is safe and feasible for people with recurrent high-grade glioma, an aggressive brain cancer. Participants receive tarlatamab infusions before their tumor is removed, then continue treatment after surgery. T…

This trial is testing whether two oral drugs, avutometinib and defactinib, can be safely given to people with newly diagnosed high-grade gliomas, a type of aggressive brain cancer. Participants first take the drugs for one cycle before starting standard radiation, and those with …

This trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This early-stage trial is testing whether infusions of natural killer (NK) cells—a type of immune cell from a healthy donor—can safely help people with advanced solid tumors that have not responded to standard treatments. The study enrolls about nine adults aged 18 to 75 and uses…

This study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. The trial includes 100 people aged 1 to 65 with tumors that have not responded to standard therapy. The goal is to see if these m…

This phase 2 trial tests three different combinations of a radioactive drug (131I-MIBG) with other medicines (vorinostat and/or dinutuximab) in children and young adults with relapsed or refractory neuroblastoma. About 118 participants will be randomly assigned to one of three tr…

This early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…

This trial tests VBC117, an investigational drug designed to attach to two proteins found on tumor cells and deliver a toxic payload directly to them. The study enrolls adults with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to …

This early-stage trial is testing a personalized cancer vaccine called BreakVax, designed from each patient's own tumor, in combination with standard chemotherapy and immunotherapy drugs. The goal is to see if this multi-pronged approach can safely and effectively boost the immun…

This study tests whether an experimental drug called SG1827, when combined with an anti-PD-1/PD-L1 antibody and bevacizumab, is safe and shows early signs of fighting advanced solid tumors. The trial enrolls adults with unresectable or metastatic solid tumors who have already tri…

This trial explores whether a special MRI technique can pinpoint low-oxygen (hypoxic) areas within glioblastoma, a type of aggressive brain tumor. In the first phase, researchers will check if these MRI maps match real tissue samples. In the second phase, they will use the maps t…

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…

This trial tests whether adding levetiracetam, a seizure medication, to the standard treatment for glioblastoma can improve outcomes. Glioblastoma is an aggressive brain cancer with poor survival despite current therapy. The study focuses on tumors with low oxygen levels, which a…

This phase II trial is asking whether adding the drug lenvatinib to the standard STUPP regimen (temozolomide plus radiation) can improve outcomes for people newly diagnosed with a type of brain cancer called glioblastoma that has a specific genetic marker (MGMT promoter methylati…

This trial tests an oral drug called JBI-778 in people with brain metastases, leptomeningeal disease, or recurrent high-grade glioma. The drug is designed to block a protein that may help tumors grow. The study aims to find the safest dose and see if the drug can shrink tumors or…

This early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This phase 2 trial is testing whether the combination of avutometinib and defactinib can stop or shrink malignant peripheral nerve sheath tumors (MPNST) that have returned or cannot be removed with surgery. The study enrolls people over 12 years old with relapsed, refractory, met…

This early-stage trial tests an experimental drug called CT-179 in people with glioblastoma, an aggressive brain cancer. The study has two parts: one for patients whose cancer has returned, and another for newly diagnosed patients who will also receive radiation therapy. The main…

This study tests a drug called tovorafenib in children and young adults (ages 1 to 39) newly diagnosed with aggressive brain tumors (high-grade glioma or DIPG) that have specific genetic changes. The goal is to see if the drug can help them live longer. About 79 participants will…

This study tests a virus called G207 combined with a small dose of radiation in children whose high-grade glioma has come back or is growing. The goal is to see if the treatment is safe and helps control the tumor. About 38 children will take part.

This pilot trial is testing a medical device called GlioHook, which is implanted in the brain after surgery to remove a high-grade glioma. The implant is designed to trap any remaining tumor cells and make follow-up radiotherapy more effective. The study includes about 15 adults …

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

This early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…

This phase 1 trial tests whether disulfiram, a drug long used for alcohol dependence, can reduce immune suppression caused by high-grade gliomas. Participants take disulfiram for 3 to 14 days before their scheduled tumor-removal surgery. The goal is to see if the drug can dampen …

This trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…

This trial tests several drugs in people with NF2-related schwannomatosis, a condition that causes tumors on nerves and in the brain. The study uses a flexible 'platform' design to evaluate treatments for four tumor types: vestibular schwannomas, non-vestibular schwannomas, menin…

This phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…

This study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…

This phase II trial tests whether a personalized dendritic cell vaccine targeting the Survivin protein can improve survival in people with newly diagnosed glioblastoma, an aggressive brain cancer. Participants receive the vaccine alongside standard chemotherapy after surgery. The…

This study tests whether the experimental drug safusidenib can slow or stop the growth of a type of slow-growing brain tumor called grade 2 glioma that has a specific genetic change (IDH1 mutation). Participants have had surgery but no other treatments like chemotherapy or radiat…

This early-phase trial tests a new way to treat recurrent glioblastoma, an aggressive brain cancer. Tiny radioactive beads called SIR-Spheres® are injected into the blood vessels feeding the tumour to deliver radiation directly inside it. The study aims to see if this approach is…

This trial tests the drug selumetinib in people with NF2-related schwannomatosis, a genetic condition that causes non-cancerous tumors on nerves, often leading to hearing loss. The study includes both adults and children whose tumors cannot be surgically removed or are growing. R…

This phase 2 trial tests whether adding nimotuzumab—an antibody that blocks a protein called EGFR—to the standard Stupp regimen (temozolomide plus radiotherapy) can improve outcomes for adults with glioblastoma that was not fully removed by surgery. Participants must have EGFR-po…

This trial tests whether combining two drugs—luvometinib (a targeted therapy) and serplulimab (an immunotherapy)—can shrink tumors and improve hearing in people with NF2-related schwannomatosis. Participants have progressive vestibular schwannomas or meningiomas that are not suit…

This early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This early-stage trial tests a new treatment for recurrent high-grade glioma, an aggressive brain cancer. The approach uses a specially designed virus injected directly into the tumor to kill cancer cells and boost the immune system, combined with a PD-1 inhibitor drug that helps…

This study explores whether a non-invasive EEG-based technique can map cognitive networks in the brain before, during, and after tumor surgery. The goal is to help surgeons avoid damaging areas critical for memory and thinking. Ten adults with brain glioma will undergo neuropsych…

This study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …

This trial compares three approaches to manage brain swelling after surgery for high-grade glioma: standard steroids (dexamethasone), no routine steroids, and a study drug called azeliragon that targets swelling through a different mechanism. The goal is to see if these alternati…

This trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…

This pilot study tests whether adding an immunotherapy drug called dinutuximab-beta to standard chemotherapy is safe and effective for people aged 1 to 30 with newly diagnosed high-risk neuroblastoma. Dinutuximab-beta is an antibody that latches onto neuroblastoma cells, helping …

This phase III trial compares a new type of MRI, called CEST MRI, to standard MRI for guiding surgery in 60 patients with newly diagnosed glioblastoma. The CEST MRI may detect tumor tissue that standard MRI misses, allowing surgeons to remove more of the cancer. The study will me…

This study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This trial tests a personalized vaccine called YS247 for people with recurrent glioblastoma, an aggressive brain cancer. The vaccine is made from each patient's own immune cells and designed to target unique markers on their tumor. The study aims to see if the vaccine is safe and…

This early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This early-phase trial tests a new combination for recurrent glioblastoma, a fast-growing brain tumor. The treatment pairs Actimab-A, a radioactive antibody that seeks out cancer cells, with cemiplimab, an immunotherapy that helps the immune system attack tumors. About 30 adults …

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This study tests whether everolimus, a drug already approved for other conditions, can safely improve social abilities in people with PTEN Hamartoma Tumor Syndrome (PHTS). About 60 adults and children with PHTS and social difficulties will take either everolimus or a placebo for …

This early-stage trial tests whether combining vorasidenib (a targeted therapy) with lomustine (a chemotherapy) is safe for people with recurrent IDH-mutant gliomas, a type of brain cancer. About 24 adults whose tumors have returned will receive different doses to find the best o…

This pilot study tests whether a device called NaviFUS, which uses ultrasound and microbubbles to temporarily open the blood-brain barrier, can safely help the drug bevacizumab reach recurrent glioblastoma tumors more effectively. Ten adults whose brain cancer has returned after …

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This study tests a new approach for recurrent glioblastoma, an aggressive brain cancer. It combines a minimally invasive laser that heats and destroys tumor tissue (LiTT) with an immunotherapy drug called cemiplimab, which helps the immune system attack cancer cells. About 99 par…

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This early-phase trial tests a new personalized vaccine called Bvax, made from each patient's own cells, combined with standard chemoradiation for newly diagnosed glioblastoma. The study will enroll 25 people to check safety and see if the vaccine helps control the cancer. It is …

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This phase 2 trial tests a single dose of FG001, a fluorescent dye, in 76 adults with newly diagnosed high-grade glioma. The dye is given before surgery and glows under a special light, helping surgeons tell tumor from healthy tissue during removal. The study checks how well the …

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This trial tests whether adding mycophenolate mofetil, a drug usually used in organ transplants, to standard radiation and chemotherapy can help people with advanced glioblastoma live longer. About 422 participants will receive either the standard treatment or standard treatment …

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This early-phase study tests a new drug called MT-125 alongside standard chemoradiation in people newly diagnosed with a specific type of glioblastoma (MGMT methylated). The goal is to find a safe dose and see how well the body handles it. About 36 adults will take part, with the…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This study looks at a new way to give radiation to children with brain tumors that need whole-brain and whole-spine treatment. The technique, called vertebral body-sparing proton therapy, aims to protect the front of the spine bones to preserve bone marrow and growth. Researchers…

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This study tests two immunotherapy drugs, fianlimab and cemiplimab, in children and young adults with recurrent high-grade glioma or ependymoma. The goal is to see if the combination is safe and can shrink tumors or slow their growth. Participants will receive the drugs before an…

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This study tests a new way to treat a rare and aggressive brain tumor called diffuse midline glioma (DMG) in the brainstem. The approach uses MRI-guided focused ultrasound to temporarily open the blood-brain barrier, allowing more of the chemotherapy drug temozolomide to reach th…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This study tests whether adding a shingles vaccine and, for some patients, specially grown immune cells (CMV-specific T cells) to standard surgery, radiation, and chemotherapy can help people with glioblastoma live longer. About 230 adults with this aggressive brain cancer will t…

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This phase 2 trial tests the drug mirdametinib, alone or with radiation, in people with NF1-related high-grade gliomas (aggressive brain tumors). It includes three groups: those with recurrent sporadic glioblastoma, newly diagnosed NF1-associated glioblastoma, and other NF1-relat…

This early-phase trial tests a new cell therapy called ThINKK in 12 children aged 2–12 who have had a stem cell transplant for leukemia or neuroblastoma. The therapy is designed to boost the body's natural killer (NK) cells to better fight cancer. The main goals are to check if t…

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This early-stage trial tests a new drug called STAR-001 combined with the blood pressure medication spironolactone in about 68 people whose glioblastoma has returned after initial treatment. The goal is to see if the combination is safe and can shrink tumors. Participants receive…

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This early-stage trial is testing a new treatment called CHT101 for adults with aggressive brain tumors that have returned or worsened despite standard care. CHT101 is a type of immune cell therapy (CAR T-cells) designed to recognize and attack tumor cells carrying a protein call…

This pilot study tests a new radiation schedule for glioblastoma, a serious brain cancer. Instead of standard daily treatments over many weeks, patients receive a higher dose each day for fewer total sessions, combined with the chemotherapy drug temozolomide. The study aims to se…

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…

This early-phase trial tests a new treatment for people whose malignant glioma (a type of brain cancer) has come back. The therapy uses the patient's own immune cells, modified to recognize and attack the cancer while also blocking a tumor defense mechanism. The study will enroll…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This early-stage trial tests whether using a special MRI-guided radiation machine (MR-Linac) can safely deliver higher, more targeted radiation doses to aggressive brain tumors (high-grade glioma). Twenty newly diagnosed patients will receive radiation twice a week for three week…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This early-stage study tests a new drug called FZ-AD005 in 40 people with aggressive brain tumors (high-grade glioma) that have come back or not responded to treatment. The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals are to find the…

This study tests a combination of chemotherapy drugs (liposomal irinotecan, vincristine, and temozolomide) with or without an additional drug (anlotinib) in children aged 3-18 whose solid tumors have returned or not responded to treatment. The goal is to see if this combination c…

This early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…

This early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…

This study tests a new treatment called MT027 for people with recurrent glioblastoma, an aggressive brain cancer. MT027 uses specially engineered immune cells (UCAR-T cells) that are injected directly into the fluid around the brain. The trial will include 40 adults aged 18-70 an…

This early-stage trial tests a new cell therapy called TH-CART-027 in 21 adults with recurrent grade 4 glioma, a very aggressive brain cancer. The therapy is given directly into the tumor or brain fluid. The main goal is to check safety and find the right dose, while also seeing …

This early-phase study tests whether combining focused ultrasound with the immunotherapy drug pembrolizumab is safe and feasible for people with recurrent glioblastoma, a severe brain cancer. Only 8 participants with a specific genetic feature (mismatch repair deficiency) will be…

This study tests whether using a smaller radiation target area after glioblastoma surgery can control the tumor while causing fewer side effects. About 79 patients will receive limited-field radiotherapy plus standard chemotherapy. The main goals are to see how many patients are …

This phase II trial tests a personalized dendritic cell vaccine (ZSNeo-DC1.1) combined with standard chemotherapy (temozolomide) in 78 adults with newly diagnosed glioblastoma. Participants receive the vaccine as shots during chemo after surgery and radiation. The goal is to see …

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …

This study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …

This early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …

This phase 2 trial tests whether adding a cancer vaccine (UCPVax) with or without an immunotherapy drug (pembrolizumab) to standard treatment can help people with a newly diagnosed, aggressive type of glioblastoma live longer. About 98 adults whose tumors have a specific genetic …

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…

This early study tests a new approach for people with slow-growing brain tumors located in areas that control movement. A small device placed on the skull delivers mild electrical stimulation while patients do physical therapy, aiming to retrain the brain so that critical functio…

This Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…

This early-stage study tests an experimental drug called gallium maltolate in 15 children whose high-grade glioma or atypical teratoid rhabdoid tumor has returned or not responded to treatment. The main goals are to find safe doses and understand side effects. Everyone receives t…

This study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…

This study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…

This study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…

This phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immu…

This early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…

This early-phase trial tests a new type of immunotherapy for recurrent glioblastoma, an aggressive brain cancer. The treatment uses a patient's own immune cells, engineered to target a protein called EGFRvIII found on tumor cells, and modified to work better in the tumor's enviro…

This early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…

This study tests a new mRNA vaccine designed to help the immune system attack cancer cells. The vaccine targets a protein found only in tumors and is given together with an immunotherapy drug (anti-PD-1). About 60 adults with advanced solid tumors that cannot be removed by surger…

This study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…

This study tests whether adding NG101m capsules to standard chemoradiation helps people with newly diagnosed glioblastoma live longer. About 52 adults will receive NG101m alongside usual care. The goal is to see if the combination is safe and improves 2-year survival.

This early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …

This early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…

This study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …

This early-phase trial tests a personalized gene therapy called KXV01 TCR Lentinvivo Injection for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a virus to deliver cancer-fighting genes into the patient's own immune cells. The …

This study tests a drug called Romiplostim N01 in 106 cancer patients whose platelets drop due to chemo, radiation, or immunotherapy. The goal is to see if it can safely raise platelet counts better than the current standard treatment. Patients will be randomly assigned to receiv…

This phase 3 trial tests whether adding two experimental drugs (Atengenal and Astugenal) to standard radiation affects heart rhythm in children aged 3–21 with newly diagnosed diffuse intrinsic brainstem glioma. The study will enroll 30 participants and monitor heart electrical ac…

This phase 3 trial tests whether adding two experimental drugs (Atengenal and Astugenal) to standard radiation therapy helps people aged 3 and older with a newly diagnosed, aggressive brainstem tumor live longer. About 92 participants will be randomly assigned to get either radia…

This early-phase trial is testing a combination of two experimental drugs, IMM2510 and IMM01, in about 104 people with advanced solid tumors that have already been treated. The goal is to find safe doses and see if the combination can shrink tumors. The study is not yet recruitin…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

This phase 2 trial tests whether romiplostim N01 can safely raise low platelet counts in 60 adults with solid tumors who have had radiotherapy combined with other treatments. The main goal is to see if platelet counts increase by at least 50 billion per liter within two weeks. Th…

This trial tests a new AI device that helps surgeons see brain tumors on ultrasound images during surgery. The AI highlights tumor tissue in real time, which may help remove more of the tumor while protecting healthy brain. The study involves 100 adults scheduled for brain tumor …

Many cancer trials require patients to have specific molecular markers, so researchers test large numbers of people to find the few who qualify. This study evaluates FATHOM, an AI system that reads clinical trial records and routine tumor slides to predict which patients carry th…

Gliomas are the most common primary brain tumors in adults, and knowing whether a tumor is low-grade or high-grade before surgery guides treatment and prognosis. Currently, doctors need a tissue sample from surgery or biopsy to grade a glioma, and standard MRI scans often cannot …

This trial is testing two new imaging tracers, called CM500, to see if they can help detect solid tumors anywhere in the body. The tracers are given by injection and then used with PET scans to create detailed images. The study includes healthy volunteers and people with various …

This study explores whether tear fluid can be used to detect tumor-related particles in people with glioblastoma, a type of brain cancer. Brain tumors release tiny particles called extracellular vesicles that can be found in spinal fluid, but collecting spinal fluid is invasive a…

This first-in-human study will test a new radioactive imaging agent called MeFAMP to see if it can safely and accurately detect brain tumors using PET scans. The study includes 28 people: healthy volunteers and patients with recurrent high-grade glioma or brain metastases from ot…

This trial is testing whether a special PET/CT scan that uses a radioactive form of tryptophan can provide better information about gliomas (a type of brain tumor) than standard MRI. The study has three parts: seeing if the scan can better define the tumor for radiation planning,…

This trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…

This study is developing an artificial intelligence (AI) system that can analyze standard MRI brain scans to determine the specific molecular subtype of a child's brain tumor before surgery. The research includes 1,400 children under 18 with suspected brain tumors, using both pas…

This trial investigates whether a special PET scan using a radioactive tracer called 18F-FET can detect brain tumors (gliomas) more accurately than standard MRI. The study includes 30 patients with suspected gliomas and 6 healthy volunteers. The goal is to see if this imaging met…

This study explores whether analyzing tumor DNA in cerebrospinal fluid can help doctors make better treatment decisions for people with malignant brain tumors or brain metastases from lung or breast cancer. Participants undergo a standard spinal tap or fluid collection, and the f…

This study tests whether oxygen-enhanced MRI (OE-MRI) can identify low-oxygen (hypoxic) regions in high-grade gliomas, the most common and aggressive adult brain cancers. Twenty-five patients will undergo OE-MRI scans before, during, and after standard radiotherapy. Researchers w…

This early-stage study will test a new radioactive tracer called [89Zr]DFO-YS5 in 40 people with nerve sheath tumors, bladder cancer, or other advanced solid tumors. The tracer is designed to bind to cancer cells and show up on PET scans, potentially making tumors easier to see. …

This early-phase study will test two radioactive tracers designed to light up certain solid tumors on scans. Twenty adults with breast, head and neck, pancreatic cancer, or glioma will receive an injection of the tracers and then undergo PET/CT and SPECT/CT imaging. The goal is t…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This early-stage trial tests a fluorescent dye called SBK2-ICG in 12 adults with untreated malignant brain tumors. The dye is given before surgery to see if it can make tumor edges glow, helping surgeons remove as much tumor as possible while protecting healthy brain. The main go…

This study tests a fast genetic test (UR-ddPCR) that checks for IDH1-mutant tumor cells in brain tissue during surgery. If the test finds leftover cancer, the surgeon can remove more tissue right away. The trial will enroll 105 adults with newly diagnosed IDH-mutant glioma at NYU…

This study compares a new type of PET/CT scan using 18F-MFBG to the current standard scan (123I-MIBG) in 30 children with relapsed or refractory neuroblastoma. The goal is to see if the new scan works as well or better for detecting tumors. If it does, it could offer a quicker an…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…

This study tests whether the supplement glutamine can prevent nerve damage caused by the chemotherapy drug vincristine in children and teens with cancer. About 70 participants, aged 6 to 18, will take glutamine twice daily for 14 days during their treatment. Researchers will trac…

Researchers at Hospital Universitario Austral in Argentina are testing whether a structured three-session music therapy program called MUSPAL360 can be delivered to hospitalized adults with advanced cancer receiving palliative care. The program combines live music therapy with 36…

Researchers are testing an experimental drug called GMDTC in adults with solid tumors who have mild kidney problems caused by cisplatin chemotherapy. The trial aims to find out if GMDTC is safe, what side effects it causes, and how the body processes it. Participants receive cisp…

This pilot trial tests whether psilocybin-assisted therapy can help adults with advanced cancer who feel demoralized, hopeless, or distressed about their illness. Participants receive a single dose of psilocybin (either 25 mg or 5 mg) during a group session, paired with either mi…

This study tests a program called Dyadic Life Review, where older adults with advanced cancer and memory problems talk through their life stories with a caregiver. The goal is to see if these conversations reduce caregiver burden and stress while bringing the pair closer together…

This pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…

This trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…

This study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…

This study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This study tests a new group self-management program for adults with brain cancer. The goal is to see if the program is practical and helps improve mental health and quality of life more than standard care. Researchers will compare changes in well-being between the group program …

This study tests a stepped-care model to support relatives of people with acquired brain injury or malignant brain tumor. The model offers basic support to all, with extra help for those who need it, based on screening. Researchers will measure changes in caregiver burden and wel…

This study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…

This pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…

This early-stage study tests whether a special MRI that highlights acidic areas can help surgeons see and remove more of an aggressive brain tumor called glioblastoma. The study involves 12 VA patients with newly diagnosed or recurrent glioblastoma. The main goal is to check if t…

This study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…

This study tests whether playing virtual reality games can help brain cancer survivors who have mild memory and thinking problems after treatment. About 40 adults who finished cancer therapy within the last two years will either use VR games or do paper word puzzles for four week…

This study tests whether virtual palliative care (via video calls) works as well as standard in-person care for adults with cancer. About 252 participants will be randomly assigned to one of the two approaches. Researchers will measure quality of life, symptom burden, and satisfa…

Researchers are observing patients in China who have both a tumor in the sellar region of the brain and an unruptured intracranial aneurysm. The study compares three approaches: removing the tumor before treating the aneurysm, treating the aneurysm before removing the tumor, or r…

This observational study aims to understand how symptoms like pain, fatigue, and nausea change over time in children with advanced cancer. Researchers will ask children aged 8 to 18 and their caregivers to complete surveys about symptoms and overall health. The goal is to identif…

This study looks back at the medical records of 350 people in Brazil diagnosed with IDH-mutant diffuse glioma, a type of brain tumor, from 2021 onward. Researchers will collect information on age, race, income, education, and other factors to build a detailed picture of who gets …

Researchers at Odense University Hospital are testing whether monitoring brain signals during tumor surgery can help preserve functions like movement, speech, and vision. The project includes a randomized trial comparing surgery with and without motor signal monitoring, plus obse…

This study investigates whether exposure to pesticides influences how aggressive a type of brain tumor called glioblastoma is and how well patients respond to treatment. Researchers will collect urine, hair, and optional blood samples from 120 adults newly diagnosed with glioblas…

This study tests whether combining PET scans with two investigational tracers, [18F]FET and [18F]FMISO, along with MRI, can help doctors place catheters more accurately for delivering therapy to recurrent brain tumors (malignant gliomas). About 20 adults already enrolled in a mai…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study tests whether real-time fMRI neurofeedback can help people with brain tumors (gliomas) shift language activity away from the tumor area before surgery. Only 4 participants will be enrolled to see if the approach is feasible, safe, and acceptable. It is a very early, sm…

This study explores whether self-administered digital cognitive tests can accurately measure thinking skills like attention, memory, and processing speed in people with primary central nervous system lymphoma or low-grade gliomas. Participants will complete both digital tests (on…

This study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 …

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study compares a new type of brain scan—watching movie clips during functional MRI (fMRI)—to standard task-based fMRI for mapping language areas in people with brain tumors (gliomas). The goal is to see if the simpler movie-watching method works as well or better for helping…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study looks at how glioblastoma, a serious brain cancer, changes the way brain cells communicate and use energy. Researchers will use special PET and MRI scans to map these changes in 80 adults before and after surgery. The goal is to link scan results with thinking and memo…

This study will test whether a special brain scan called magnetoencephalography (MEG) can detect electrical differences within gliomas, the most common malignant brain tumors in adults. Researchers will scan 60 newly diagnosed patients before surgery to see if MEG can identify mo…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This study looks at how the immune system changes in people with glioblastoma, an aggressive brain cancer, after they have surgery and chemotherapy. Researchers will take blood samples over six months to measure immune cells and signals. The goal is to understand the body's immun…

This study tests whether using MRI scans to plan radiotherapy is better than using CT scans alone. Researchers will work with up to 150 cancer patients and 15 healthy volunteers to see if MRI can make treatment more precise and reduce side effects. The goal is to improve how tumo…

This study tests a new type of MRI called Field-Cycling Imaging (FCI) to see if it can tell the difference between real tumor growth and pseudo-progression (which looks like tumor but isn't) in adults with glioblastoma. Eighteen patients will get both a standard MRI and an FCI sc…

This study tests whether special MRI scans can spot where brain tumors have spread into nearby healthy tissue, which standard scans miss. About 20 adults with suspected high-grade glioma will get extra scans before surgery. The results will be compared to tissue samples to see if…

This early-stage trial will test whether an oral drug called gallium maltolate can reach brain tumors in people with recurrent glioblastoma. Eight participants will take the drug for about two weeks before surgery, and researchers will measure gallium levels in the removed tumor …

This early study tests whether a small device can safely collect fluid from the brain during planned surgery for glioma or epilepsy. Six participants will have the device placed temporarily during their operation. The goal is to see if the device works and is safe, not to treat t…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study looks at how male hormones (androgens) influence the immune cells around glioblastoma tumors, the most common and aggressive brain cancer in adults. Researchers will collect blood, saliva, and stool samples from 40 newly diagnosed patients before and after standard che…

This study looks at whether a special PET scan (18F-AGX) can detect early changes in brain tumor activity in adults with slow-growing IDH-mutant gliomas who are taking the drug Vorasidenib. Ten participants will get the drug daily for about a year and have multiple PET and MRI sc…

This study tests whether physical therapy, alone or with brain stimulation, can help rewire the brain before surgery for high-grade glioma near the motor area. About 63 adults with preserved movement will be randomly assigned to standard care, therapy, or therapy plus stimulation…

This study will test whether a mobile app called Resilience PRO can help monitor symptoms and quality of life in 80 adults with IDH-mutated glioma who are starting a new systemic treatment. Participants will use the app to report side effects and complete questionnaires every two…

This study tests giving chemotherapy before radiation for people with high-grade gliomas, a type of aggressive brain tumor. The goal is to see if this approach works well and makes MRI scans easier to read, since radiation can change how the brain looks. About 70 adults aged 18-8…

This study tests a special microscope accessory called GLOW400 that helps surgeons see glowing brain tumors during surgery. About 37 adults with suspected high-grade gliomas will take part. Surgeons will rate how well the device shows tumor fluorescence and image quality. The goa…

This study follows 93 children aged 5-18 with brain tumors who are receiving radiation therapy. Researchers will track their nutrition and quality of life over time to see how they are connected. The goal is to create a nutrition plan and early warning system to help these childr…

This study tests how well the MyVeo surgical headset shows surgical details during routine brain, spine, ear-nose-throat, or reconstructive surgeries. Surgeons will rate image quality, comfort, and safety while using the device. About 32 patients will take part, and no extra proc…

This study will include 30 people newly diagnosed with glioblastoma, the most common and aggressive brain tumor. Researchers will use a special MRI technique called magnetic resonance spectroscopy (MRS) to measure chemicals in the tumor, and also test blood for certain markers. T…

This study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …

This study aims to adapt a questionnaire called PROFFIT, originally developed in Italy, to measure financial toxicity (the financial burden of cancer treatment) in Turkish patients. Researchers will enroll 320 adults with cancer who have received treatment in the last three month…

This observational study looks at how immune checkpoint inhibitors (a type of cancer immunotherapy) affect ovarian function and fertility in women aged 18-38 with solid tumors. Researchers will collect blood and stool samples before and during treatment to measure hormone levels …

This study will follow 50 adults with glioblastoma, an aggressive brain cancer, to see how the amount of tumor removed during surgery affects how long they live. All patients will receive standard radiation and chemotherapy after surgery. The goal is to better understand which su…

This study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…

This study looks back at medical records of 150 children who had surgery for neuroblastic tumors in the lower chest. Some had a special X-ray (arteriography) before surgery to map a key spinal artery, while others did not. Researchers want to see if the imaging helps prevent spin…

This study tests a special camera attached to a surgical microscope to see if it can better detect glioma tumor cells during brain surgery. Researchers will observe 80 adults with suspected high-grade gliomas. The goal is to improve how surgeons see tumor tissue, not to test a ne…

This study will follow 100 adults with glioblastoma, an aggressive brain cancer, to understand which factors influence survival. Researchers will collect data on patient characteristics, tumor features, surgical methods, and outcomes. The goal is to identify the best surgical str…

This study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…